Programme

Overview: Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will be recorded and made available via the online platform and mobile app.

Overview: Poster Discussions are presented in one of the sessions scheduled at the two poster discussion theatres. Each author will present a digital poster orally for 2 minutes, followed by 2 minutes for discussion. Sessions will be recorded and made available via the online platfrom and mobile app.

Overview: Poster Discussions are presented in one of the sessions scheduled at the two poster discussion theatres. Each author will present a digital poster orally for 2 minutes, followed by 2 minutes for discussion. Sessions will be recorded and made available via the online platfrom and mobile app.

Overview: This session explores how modern technology is enabling faster, simulation-free radiotherapy while maintaining safety, precision, and clinical value. It will open with an overview of the direct-to-treatment paradigm, illustrating how same-day radiotherapy without prior CT simulation is becoming feasible, supported by clinical examples and data. The following talks will highlight both clinical and physics considerations, including workflow adaptation, patient selection, implementation strategies, and dosimetric implications. The session aims to provide a comprehensive view of this emerging approach, stimulate discussion on challenges and opportunities, and reflect on how it may shape the future of routine radiotherapy practice.

Overview: Biochemical recurrence (BCR) after primary local treatment for prostate cancer remains a clinical challenge. Recent evidence suggests that high-risk non-metastatic BCR, defined by a rapid PSA doubling time, warrants systemic treatment intensification with androgen receptor pathway inhibitors, which significantly delay metastasis, disease progression, and potentially improve survival. Next-generation imaging, particularly PSMA-PET, enables earlier detection of oligometastatic disease, refining treatment strategies. This has led to growing interest in metastasis-directed therapy (MDT), such as SBRT, as a means to improve clinical outcome in this disease setting. Emerging data indicate that MDT, either alone or in combination with systemic treatment, can improve progression-free survival and delay systemic progression. However, key questions remain regarding optimal patient selection, treatment sequencing, and long-term outcomes. This session will provide a state-of-the-art overview of management of high-risk BCR after prostate cancer primary local treatment, addressing current evidence and unmet clinical needs to refine personalized treatment strategies.

Overview: Artificial Intelligence is revolutionizing radiation therapy, but how can we ensure a safe, effective, and clinically validated implementation? In this must-attend session Barbara Jereczek introduces the ESTRO-AAPM AI guideline, a roadmap for developing, validating, and reporting AI models in clinical practice. Wouter van Elmpt will showcase applications in different domains. Discussed will be automation tasks such as AI-driven segmentation that are being introduced clinically. In addition, AI applications in the field clinical decision support systems and outcome prediction will be discussed, while debating whether clinics are ready to embrace these innovations. Interactive panel discussions will tackle key challenges, regulatory hurdles, and future perspectives. If you’re looking to integrate AI into your practice with confidence, this session is essential.

Overview: The teaching lecture will provide an overview of the main techniques used for image guidance in radiotherapy and the recent developments in this field. The lecture will focus on the most central in-room imaging modalities, including x-ray, MRI and surface guided radiotherapy (SGRT). For each of these the lecture will cover their use in patient setup, motion management and potential for adaptive radiotherapy. The presentation will mainly be relevant for photon therapy, but will give some examples on differences and similarities of the use of these techniques also in proton therapy. Perspective on emerging image guidance methods will be briefly discussed.

Overview: In this session we welcome our two multidisciplinary speakers from The Catharina Cancer Institute in Eindhoven, The Netherlands. During this session we will have the opportunity to learn first-hand how deep learning segmentation (DLS) has been implemented in their clinic, and how this process has changed their practice. Firstly, Clinical Physicist, Coen Hurkmans, will consider the motivation to implement DLS practices in a clinical environment. Drawing on evidence from the literature, he will highlight achievable results, common pitfalls, and strategies to mitigate errors in segmentation. He will also provide us with a comprehensive guide to evaluating the quality of segmentations within clinical workflows. Coen will also address the how to establish a multidisciplinary team to support the implementation phase of DLS. His talk will then be followed up by RTT colleague, Melissa Verdonk-van den Heuvel. Melissa will talk us through the practicalities of introducing DLS, using examples from various imaging technologies, including CBCT and MRI. She will also highlight the outcomes of testing protocols, and the ongoing quality assurance measures in place critical to the success of DLS. Finally, Melissa will discuss the evolving roles of radiation therapists (RTTs) in this changing landscape and explore potential future opportunities for advanced practice.